CD4 lymphocyte regenerative capacity was evaluated by use of an ex vivo outgrowth assay in human immunodeficiency virus (HIV)-1-infected subjects enrolled in a clinical trial (Merck 039). CD4 lymphocytes were selectively expanded in vitro by T cell receptor triggering, which also induces HIV production from latently infected cells. CD4 cell expansion and lack of virus production in cultures correlated well with clinical responses and were best in those receiving an aggressive antiretroviral three-drug regimen. Twelve clinical responders receiving tripledrug therapy monitored for 60 weeks had both excellent ex vivo CD4 cell expansion and lack of HIV replication, often in the absence of added drug in culture. Breakthrough viruses recovered from drug-containing arms of the cultures showed phenotypic resistance to the drugs used in vivo. This CD4 lymphocyte outgrowth assay correlates well with clinical outcome in subjects receiving potent antiretroviral regimens and may predict the emergence of early drug resistance.
phocytes are cultured in the presence or absence of antiretroviral drugs, singly or in combination [5] . If substantial viral replication occurs in these cultures, CD4 lymphocytes are infected and killed, whereas in the absence of viral replication, unrestricted CD4 lymphocyte outgrowth occurs. This assay has been evaluated in previous studies with individual patients receiving various three-drug antiretroviral combinations but not in the context of a controlled clinical trial.
In this report, we evaluate the associations between the ability of CD4 lymphocytes from drug-treated subjects to expand ex vivo and clinical responses to individual treatment regimens in the context of a blinded clinical trial (Merck 039).
Materials and Methods
Patient population. The Merck 039 trial studied subjects who were HIV-1 seropositive, had CD4 cell counts р50 cells/mm 3 , and had been previously treated with zidovudine for у6 months. Patients were excluded if they had had prior treatment with any protease inhibitor or lamivudine. Patients were randomized in doubleblind fashion to one of three treatment arms: indinavir, 800 mg every 8 h; zidovudine, 300 mg twice daily plus lamivudine, 150 mg twice daily; or all three drugs.
CD4 lymphocyte outgrowth assays were done on patients enrolled at three Boston sites (Massachusetts General Hospital, Brigham and Women's Hospital, Fenway Community Health Center). Heparinized blood was drawn at three time points: baseline, after 12 (or 16) weeks of therapy, and at the conclusion of the randomized treatment period (24 weeks). At that point, patients were offered open-label treatment with indinavir, zidovudine, and lamivudine. Twelve patients receiving three drugs after week 24, including 7 from the initial three-drug arm, one from the initial zidovudine plus lamivudine arm, and 4 from the initial indinavir arm, were followed for up to 60 weeks. Treatment assignments were not known to investigators conducting or evaluating the CD4 lymphocyte outgrowth assay.
Ex vivo expansion. After isolation on a ficoll-hypaque density gradient (Histopaque-1077; Sigma, St. Louis), peripheral blood mononuclear cells (PBMCs) were resuspended at 10 6 /mL in 24-well tissue culture plates (Becton Dickinson, Lincoln Park, NJ) in RPMI 1640 medium (Sigma) supplemented with 10% heat-inactivated fetal calf serum (Sigma), penicillin (50 U/mL), streptomycin (50 mg/ mL), L-glutamine (2 mM), HEPES buffer (10 mM), and 100 U/ mL recombinant human interleukin-2 (Hoffman-La Roche, Nutley, NJ). Fractionated PBMCs ( ) were divided equally into 6 4 ϫ 10 culture under four different conditions: no drug treatment, indinavir (0.4 mM) (Merck Research Laboratories, West Point, PA), zidovudine (0.5 mM) (Glaxo Wellcome, Research Triangle Park, NC) plus lamivudine (3.0 mM) (Glaxo Wellcome), and indinavir (0.4 mM) plus zidovudine (0.5 mM) plus lamivudine (3.0 mM). Simultaneously, a CD3:8 bispecific monoclonal antibody, which selectively depletes CD8 cells while activating CD4 cells [6] , was added at a final concentration of 4 mg/mL.
Cell cultures were incubated at 37ЊC in a humidified 5% CO 2 atmosphere. Cultures were maintained for a 21-day period with twice-weekly exchanges of medium plus or minus drug(s). Cell-free supernatants were collected weekly for measurement of HIV-1 p24 antigen production by ELISA (DuPont-NEN Research Products, Boston). After 2 weeks in culture, cells were collected for the measurement of CD4 and CD8 T lymphocyte populations by threecolor staining for CD3, CD4, and CD8 expression with fluorescein isothiocyanate-conjugated monoclonal antibody and analyzed by flow cytometry. A satisfactory expansion was defined arbitrarily as a percentage of CD4 cells 140% of the total expanded cell population. Similar results were obtained if the criterion was a higher percentage of CD4 cells (50% or 60%).
HIV-1 DNA detection by polymerase chain reaction (PCR). After 21 days in culture, aliquots of cells were pelleted in 6 5 ϫ 10 a microcentrifuge and stored at Ϫ70ЊC, and subsequently total genomic DNA was extracted (Gentra Systems, Minneapolis). Uninfected donor PBMCs were also collected as negative controls. Each reaction contained a DNA equivalent of 10 5 cells. HIV-1 DNA was detected by use of nested PCR with pol and env primers under conditions that detected 1 copy of control HIV-1 DNA based on serial dilutions of HIV-1-positive control plasmid DNA (PerkinElmer, Branchburg, NJ).
PCR primers that hybridized to the pol gene were HPOL4238-4538 for the outer primer set and HPOL4327-4481 for the inner nested primer set [7] . Primers that hybridized to the env gene were HENV5944-6154 for the outer primer set and HENV6009-6135 for the inner nested primer set [7] . Primers GH28 and GH29, which detect the cellular DQb gene, were used as a control of DNA quality for amplification. Primary amplification mixtures using outer primers for both HIV-1 genes consisted of 50 mL containing 1.5 mM Mg(OAc) 2 , 100 mM each dNTP (Pharmacia, Piscataway, NJ), 0.2 mM each primer, and 0.5 U of rTth DNA polymeraseXL (Perkin-Elmer).
The PCR thermal protocol was as follows: 94ЊC for 4 min; then 28 cycles at 94ЊC for 30 s, 50ЊC for 15 s, and 72ЊC for 30 s; and, finally, an extension step of 72ЊC for 2 min. Secondary amplification was done with 2 mL of a 1:10 dilution of the first reaction products and amplification with the appropriate nested amplification primer sets. This inner nested PCR mixture was identical except for using 2.0 mM Mg(OAc) 2 and 200 mM each dNTP (Pharmacia). Cycling conditions used for secondary amplification were as follows: 94ЊC for 1 min; then 25 cycles of 94ЊC for 30 s, 53ЊC for 15 s, and 72ЊC for 30 s; and, finally, an extension step of 72ЊC for 2 min. DQb control amplification was the same as the outer PCR but used 35 cycles.
PCRs were all done with a hot-start with AmpliWax (PerkinElmer). Each reaction included multiple negative controls (consisting of H 2 O control of outer and nested PCRs, resuspension buffer after lysis, and uninfected PBMCs at the same concentration as the rest of the samples) and a positive control. Amplified DNA fragments were analyzed by 2% agarose gel electrophoresis and stained with ethidium bromide.
Serum HIV-1 RNA and CD4 cell counts. Both standard (Amplicor; Roche Diagnostic Systems, Branchburg, NJ) and ultrasensitive (Ultradirect; Roche) HIV-1 quantitative RNA PCR assays were done centrally by Merck Research Laboratories on blinded serum specimens at protocol-specified intervals from all patients enrolled in the study. CD4 cell counts were also done centrally at the same time intervals.
Drug susceptibility assay. Titers of virus recovered from expansion cultures containing drugs were determined by an end-point titration method in 96-well microtiter plates. A 1000-5000 TCID 50 inoculum of virus stock was used to infect 10 6 phytohemagglutininstimulated donor PBMCs in the presence of serial drug dilutions. After 4 days, p24 antigen production was measured in the cell-free supernatant of each well, and the drug concentrations required to inhibit p24 antigen production by 50% (IC 50 ) compared with drugfree controls were determined.
Statistical analysis. Ex vivo and in vivo virus suppression were compared by Fisher's exact test.
Results
During the first 24 weeks of therapy, the best clinical responses were seen in those patients receiving the three-drug antiretroviral regimen of indinavir, zidovudine, and lamivudine compared with responses in those receiving two drugs or monotherapy regimens. Clinical response was defined arbitrarily as either a 4-fold increase in peripheral blood absolute CD4 cell count and/or a decrease of 10.5 log in serum HIV-1 RNA/mL. If different response definitions, such as a decrease of 1 log in serum HIV-1 RNA or a 5-fold increase in absolute CD4 cell count, were used, no substantial differences in results were seen. All 8 patients randomized to the three-drug arm had a у4-fold increase in CD4 cell count and 7 of 8 had a decrease of 10.5 log in serum HIV-1 RNA. Five of these 8 achieved undetectable levels of serum HIV-1 RNA as determined by the Amplicor assay (limit of detection, !500 copies/mL); when tested with the ultrasensitive method (limit of detection, !50 copies/mL), 3 had undetectable HIV-1 RNA (table 1; figure 1) .
The expansion capacity of CD4 cells from subjects receiving the various drug regimens was assessed ex vivo. At weeks 0, 12, and 24, PBMCs were stimulated with an antibody that results in selective expansion of CD4 cells and inhibits CD8 cells. By activating CD4 cells in the absence of CD8 cells, one can determine if viral replication is inhibited by the drugs being used. One can also evaluate the ability of these cells to expand. The input percentage of CD4 cells in the cultures did not vary significantly over time or within the three treatment arms and, therefore, was not likely to influence the expansion capacity of these cells. The 8 patients randomized to the three-drug regimen had successful expansion of CD4 lymphocytes ex vivo ( figure  1 ). In the expansion cultures from these patients, 7 had undetectable p24 antigen in the presence of drug, and in 2 of these, p24 antigen was undetectable even in the absence of added drug (table 1) . These data indicate that this triple-drug regimen is associated with both a good regenerative capacity of the CD4 lymphocytes and effective virus suppression ex vivo.
Nine patients were randomized to the indinavir monotherapy group. All 9 had clinical responses as shown by either a decrease of 10.5 log in serum HIV-1 RNA (8/9) and/or a 4-fold increase in absolute CD4 cell count (7/9). However, when we assessed the ex vivo expansion capability of CD4 lymphocytes from these 9 patients, only 6 had a successful expansion. In these cultures, p24 antigen was detectable in the absence of drug in 6 and in the presence of indinavir in 4 (table 2). Two of these 6 patients had cultures with undetectable p24 antigen in the presence of indinavir (patients 9 and 13), and of these 2, only 1 (patient 13) achieved undetectable levels of serum HIV-1 RNA. For 3 patients in this indinavir monotherapy group, attempts at CD4 lymphocyte expansion were not successful. In expansion cultures of 2 of these 3 patients, p24 antigen was detectable in the presence of either no drug or indinavir alone. In expansion cultures of the third patient, p24 antigen was detectable in the absence of drug but not detected in the presence of indinavir. This was the only patient of these 3 to achieve undetectable serum levels of HIV-1 RNA. The fact that virus could be readily recovered from most cultures containing indinavir in this group of 9 patients receiving indinavir monotherapy suggests that this therapy is less effective than three-drug therapy (6/9 cultures with detectable p24 antigen in the indinavir group vs. 1/8 in the three-drug group; , Fisher's exact test) and that this assay can be P ϭ .05 used to identify subjects who may be developing resistance to indinavir (see below).
In the zidovudine plus lamivudine group, only 3 of 6 subjects had a clinical response, as defined by a 4-fold increase in CD4 cell count and/or a decrease of 10.5 log in serum viral RNA (table 3) . Successful ex vivo CD4 cell expansions were obtained in 4 of 6; however, p24 antigen was always detectable in these cultures in the absence of drug. In 2 cultures, p24 antigen was also detectable in the presence of zidovudine plus lamivudine. For two subjects in the zidovudine plus lamivudine group, attempts at CD4 lymphocyte expansion were not successful, in either the presence or absence of zidovudine plus lamivudine, although both patients had a good clinical response. In expansion cultures from 1 of these patients, p24 antigen was detectable. These data suggest that therapy with zidovudine plus lamivudine was less effective than the three-drug therapy, although the numbers studied were too small to show statistical significance (3/3 cultures with detectable p24 antigen in the twodrug group vs. 1/7 in the three-drug group; , Fisher's P ϭ .24 exact test).
Twelve patients were followed for up to 60 weeks of treatment. All of these had received three-drug therapy from at least week 24. All 12 had clinical responses (table 4): 10/12 showed a 14-fold increase in CD4 cell count and had a 10.5-log decrease in serum RNA. Of these, 8 had undetectable RNA levels as determined by the Amplicor assay and 6 had !50 copies/mL when tested with the ultrasensitive method. Attempts at expanding CD4 lymphocytes ex vivo were successful for all 12 patients in this group. In the expansion cultures of these 12 patients, 7 had undetectable p24 antigen in the absence of drug and 10 had undetectable p24 antigen in the presence of drug. Data from this extended analysis confirm that effective therapy results in good regenerative capacity of CD4 lymphocytes ex vivo and that virus suppression can be achieved in these cultures with the same regimen used in vivo. The two cases in which viral replication occurred in the presence of drugs suggest that viral resistance developed to one or more drugs contained in the regimen (see below).
Phenotypic resistance was determined for 7 virus isolates recovered from cultures containing the identical drug regimen Table 4 . CD4 lymphocyte outgrowth and clinical outcome in 12 patients with good clinical responses followed to 60 weeks. that patients were receiving in vivo. "Resistance" was defined as a 4-fold increase in IC 50 compared with that of a wild-type clinical strain. Of these 7 isolates, 4 were from indinavir-containing cultures of patients receiving indinavir monotherapy in vivo. All 4 isolates were resistant to indinavir, with IC 50 s ranging from 0.11 to 0.73 mM. Three isolates were from zidovudine plus lamivudine-containing cultures of patients receiving zidovudine plus lamivudine in vivo. These 3 isolates were all resistant to lamivudine, with IC 50 s 15.0 mM. Two of these isolates also showed resistance to zidovudine, with IC 50 s of 0.60 and 0.06 mM, respectively. The zidovudine IC 50 for the other isolate was 0.01 mM. In our laboratory, the indinavir IC 50 for the control wild-type isolate is 0.02 mM; the zidovudine IC 50 , !0.01 mM; the lamivudine IC 50 , 0.15 mM. These results confirm that the recovery of virus from drug-containing cultures correlates with a resistance phenotype of these viruses.
Nested PCR assays were done on cells obtained after 21 days of cultures without added drugs from 6 patients in the group followed for up to 60 weeks of treatment (table 4) to evaluate whether HIV-1 DNA could be recovered from successfully expanded cultures that did not produce p24 antigen. All p24 antigen-negative CD4 cell expansion cultures assayed by PCR at week 60 of treatment were still positive for HIV-1 DNA (6/6). Table 5 shows summary comparisons of HIV-1-suppressive regimens in vivo and ex vivo across the different groups studied at week 24. Maximal HIV-1 suppression, as defined by serum HIV-1 RNA values of !50 copies/mL achieved during therapy, was associated with virus suppression in culture, as defined by undetectable HIV-1 p24 antigen in cultures containing the same drug regimens as the patients were receiving ( , Fisher's P ϭ .045 exact test; table 5). Data at week 60 also indicated that maximal HIV-1 suppression in vivo was strongly associated with virus suppression in culture in the absence of drug (table 4) . Partial to no virologic responses in vivo were mirrored by ineffective virus suppression in culture, even in the presence of drugs that the patient had received, suggesting that resistant virus might be emerging.
Discussion
Previous studies have shown that mitogenic or antigenic stimulation of HIV-1-infected CD4 lymphocytes results in increased HIV-1 replication, leading to viral dissemination and cell death [8] [9] [10] . In contrast, effective inhibition of viral replication should result in a successful expansion of CD4 lymphocytes. This was previously demonstrated in an ex vivo expansion assay of CD4 lymphocytes from HIV-1-infected persons in the presence of three reverse transcriptase inhibitors [5] . We hypothesized further that if a patient is receiving an effective treatment regimen, the virus should be sufficiently suppressed to permit ex vivo expansion of his or her CD4 lymphocytes. However, if viral replication is not adequately suppressed in vivo, the addition, to the culture system, of drugs to which the virus is susceptible should permit the recovery of CD4 lymphocyte expansion capacity unless the cell population is no longer capable of expansion. This CD4 expansion assay offers an entirely autologous system that samples circulating populations of autologous lymphocytes and virus ex vivo and may more accurately reflect HIV-1 and lymphocyte dynamics in an infected person than do other heterologous in vitro cell culture systems.
Our data suggest that even in a population of persons with advanced HIV-1 infection, the correlation of successful CD4 cell expansion and HIV-1 suppression in culture with clinical response is excellent when a potent antiretroviral regimen is used. As expected, the best expansion responses were seen in the triple-drug antiretroviral combination group, which is consistent with the clinical results of this study [11] . All 8 patients who received triple antiretroviral therapy in this clinical trial substudy had both good clinical outcomes and successful CD4 lymphocyte expansions. Seven of these 8 also had good virus suppression in culture. A group of 12 patients followed for 60 weeks, all of whom had been receiving triple-drug therapy from at least week 24 to week 60, also showed clinical responses and good ex vivo CD4 lymphocyte expansion; virus suppression was observed in culture in 10 of the 12. The undetectability of p24 antigen in culture supernatants, in the presence or absence of exogenously administered drugs, was mirrored by very low serum HIV-1 RNA levels in vivo.
The fact that HIV-1 DNA could still be detected in cultured cells in the absence of productive infection is consistent with recent data suggesting that proviral DNA may persist in latently infected resting cells, despite effective antiretroviral therapy [2, 3] . Studies have shown that a minority of proviral DNA in latently infected lymphocytes may represent replicationcompetent virus, which can be recovered by enhanced culture methods [2, 3, 12] . It has not yet been determined whether the proviral DNA detected in our cultured lymphocytes represents replication-competent or defective virus.
Clinical responses and CD4 cell expansions were more variable in two other study arms that received regimens less likely to achieve profound virus suppression (zidovudine plus lamivudine or indinavir monotherapy). Overall, CD4 cell expansions correlated less well with clinical responses in these suboptimally treated patients.
The viruses recovered from ex vivo expansions in the presence of drug regimens being administered in vivo were phenotypically drug-resistant, similar to our earlier results [5] . Indinavir resistance and dual zidovudine plus lamivudine coresistance are not selected in vitro with short-term passage in high drug concentrations, such as the concentrations used here, which inhibited 99% of replication of wild type virus. Therefore, these data suggest that at least a minority of drug-resistant virus was present in these patients' PBMCs in vivo.
In summary, CD4 lymphocyte expansion and virus suppression in expansion cultures correlated well with clinical outcome in patients receiving potent antiretroviral therapy. It will be of interest to determine whether satisfactory ex vivo expansion in the absence of exogenous drug will predict long-term clinical responses and/or help identify those patients whose therapy may be modified to a simpler, better-tolerated maintenance regimen or who may eventually discontinue therapy. Such studies are under way. In patients with detectable serum or plasma HIV-1 RNA, a relatively simple and rapid analysis of p24 antigen in the drug-containing arms of an expansion culture may allow one to predict emergence of drug-resistant virus in vivo and to switch to a more appropriate regimen early in the process of drug failure. Breakthrough viral replication can occur in vivo in the absence of detectable drug resistance to all components of a regimen [13] . Thus, early ex vivo detection of specific susceptibility patterns might allow finer tuning of multidrug regimens than is currently recommended. Additional studies will be needed to assess this hypothesis and determine whether these findings can be applied to other treatment regimens and different patient populations.
